River Front Investment Group, LLC Incyte Corp Transaction History

River Front Investment Group, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 02, 2021	SELL	$68.67 - $84.02 $208,688 - $255,336	-3,039 Closed	0 $0
Q2 2021 Aug 09, 2021	BUY	$79.87 - $87.53 $9,504 - $10,416	119 Added 4.08%	3,039 $256,000
Q1 2021 Apr 29, 2021	BUY	$76.02 - $100.5 $35,653 - $47,134	469 Added 19.14%	2,920 $0
Q4 2020 Feb 03, 2021	BUY	$80.74 - $97.7 $197,893 - $239,462	2,451 New	2,451 $213,000

644

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.8B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of River Front Investment Group, LLC, based on Form 13F filings with the SEC.

Stay updated on River Front Investment Group, LLC with notifications on news.